Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENC NASDAQ:HUMA NASDAQ:IMA NASDAQ:NBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$9.24+36.5%$6.86$5.65▼$9.92$319.16M0.91177,649 shs2.27 million shsHUMAHumacyte$1.00-11.5%$0.85$0.55▼$2.93$222.02M2.316.54 million shs10.09 million shsIMAImageneBio$5.91+2.4%$5.63$3.94▼$18.00$62.94M0.73253,061 shs10,754 shsNBPI-Mab$1.92-6.3%$2.59$0.85▼$6.79$222.05M1.56907,644 shs711,717 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies-3.70%-5.71%+14.17%-17.44%+4.48%HUMAHumacyte+24.18%+14.92%+68.63%+11.88%-34.68%IMAImageneBio+0.87%-5.10%-4.63%-15.77%-58.55%NBPI-Mab+0.49%-8.00%-13.75%-36.11%+206,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$9.24+36.5%$6.86$5.65▼$9.92$319.16M0.91177,649 shs2.27 million shsHUMAHumacyte$1.00-11.5%$0.85$0.55▼$2.93$222.02M2.316.54 million shs10.09 million shsIMAImageneBio$5.91+2.4%$5.63$3.94▼$18.00$62.94M0.73253,061 shs10,754 shsNBPI-Mab$1.92-6.3%$2.59$0.85▼$6.79$222.05M1.56907,644 shs711,717 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies-3.70%-5.71%+14.17%-17.44%+4.48%HUMAHumacyte+24.18%+14.92%+68.63%+11.88%-34.68%IMAImageneBio+0.87%-5.10%-4.63%-15.77%-58.55%NBPI-Mab+0.49%-8.00%-13.75%-36.11%+206,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 2.57Moderate Buy$14.8060.17% UpsideHUMAHumacyte 2.75Moderate Buy$7.57657.14% UpsideIMAImageneBio 2.00Hold$26.50348.39% UpsideNBPI-Mab 2.00Hold$9.00368.75% UpsideCurrent Analyst Ratings BreakdownLatest IMA, HUMA, FENC, and NBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform5/4/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/28/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/28/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/21/2026FENCAdherex Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/16/2026FENCAdherex Technologies WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.004/10/2026HUMAHumacyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026NBPI-Mab HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/27/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$44.64M7.15N/AN/A$1.04 per share8.88HUMAHumacyte$2.04M108.83N/AN/A$0.02 per share50.00IMAImageneBio$800K78.68N/AN/A$11.57 per share0.51NBPI-Mab$3.89M57.08N/AN/A$2.00 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$9.74M-$0.34N/A10.87N/A-22.62%-183.18%-15.31%5/14/2026 (Estimated)HUMAHumacyte-$40.83M-$0.20N/AN/AN/A-1,998.87%-990.48%-74.79%N/AIMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/ANBPI-Mab-$46.27M-$0.36N/AN/AN/AN/AN/AN/AN/ALatest IMA, HUMA, FENC, and NBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FENCAdherex Technologies-$0.02$0.01+$0.03$0.01$13.90 million$15.11 million5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A4/8/2026Q4 2025NBPI-MabN/A-$0.2990N/A-$0.2990N/AN/A3/27/2026Q4 2025HUMAHumacyte-$0.13-$0.13N/A-$0.13$1.35 million$0.47 million3/24/2026Q4 2025FENCAdherex Technologies$0.0423-$0.17-$0.2123-$0.17$14.75 million$13.78 million3/24/2026Q4 2025FENCAdherex Technologies$0.03-$0.17-$0.20-$0.17$14.73 million$13.78 million3/10/2026Q4 2025IMAImageneBioN/A$0.34N/A$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/ANBPI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A6.376.23HUMAHumacyte20.083.692.95IMAImageneBioN/A18.3912.49NBPI-MabN/A8.098.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%HUMAHumacyte44.71%IMAImageneBio75.00%NBPI-Mab38.38%Insider OwnershipCompanyInsider OwnershipFENCAdherex Technologies10.73%HUMAHumacyte3.10%IMAImageneBio5.94%NBPI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex Technologies1034.54 million30.84 millionOptionableHUMAHumacyte150222.02 million215.14 millionOptionableIMAImageneBio7010.65 million10.02 millionNot OptionableNBPI-Mab380115.65 million90.09 millionN/AIMA, HUMA, FENC, and NBP HeadlinesRecent News About These CompaniesNovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12 at 7:00 AM | globenewswire.comMark Arnold Hagler Buys 230,000 Shares of I-Mab (NASDAQ:NBP) StockApril 29, 2026 | insidertrades.comInsider Buying: I-Mab (NASDAQ:NBP) Insider Buys 230,000 Shares of StockApril 28, 2026 | marketbeat.comNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueApril 22, 2026 | globenewswire.comNovaBridge's Givastomig Could Drive A Major Re-RatingApril 9, 2026 | seekingalpha.comNovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateApril 7, 2026 | globenewswire.comNovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerMarch 16, 2026 | globenewswire.comNovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD StudyMarch 9, 2026 | globenewswire.comNovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026March 3, 2026 | globenewswire.comNovaBridge to Present at the Leerink Partners 2026 Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comNovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech PlatformFebruary 19, 2026 | globenewswire.comNovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerFebruary 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAlphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026These 3 Defense Giants Beat Q1 Estimates—So Why Did Their Stocks Still Fall?By Jessica Mitacek | April 22, 2026Corning Beats Q1 Estimates but Drops 9% on Guidance MissBy Ryan Hasson | April 29, 2026Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales TankBy Leo Miller | April 27, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 2026IMA, HUMA, FENC, and NBP Company DescriptionsAdherex Technologies NASDAQ:FENC$9.24 +2.47 (+36.48%) Closing price 04:00 PM EasternExtended Trading$9.22 -0.02 (-0.16%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Humacyte NASDAQ:HUMA$1.00 -0.13 (-11.50%) Closing price 04:00 PM EasternExtended Trading$1.02 +0.02 (+2.00%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.ImageneBio NASDAQ:IMA$5.91 +0.14 (+2.43%) Closing price 04:00 PM EasternExtended Trading$5.88 -0.03 (-0.51%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.I-Mab NASDAQ:NBP$1.92 -0.13 (-6.34%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.02 (+1.04%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
